MP14-18 NEOADJUVANT COMBINATION OF PAZOPANIB OR AXITINIB AND PD-1-ACTIVATED DC-CIK CELLS IMMUNOTHERAPY MAY FACILITATE SURGERY IN PATIENTS WITH RENAL CELL CARCINOMA

Authors :: Pei Dong
Chunping Yu
Longbin Xiong
Ya Ding
Fangjian Zhou
Hui Han
Zeshen Wu
Shengjie Guo
Desheng Weng
Huiming Liu
Lijuan Jiang
Yulu Peng
Zhiling Zhang
Jianchuan Xia
Kang Ning
Source :: Journal of Urology. 206
Publication Year :: 2021
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2021.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Urology
medicine.medical_treatment
Immunotherapy
medicine.disease
Axitinib
Pazopanib
Renal cell carcinoma
Internal medicine
medicine
In patient
business
medicine.drug

Tools